Home > About > Officers and Committees > Inflammatory Bowel Disease Committee > Guideline Development Group Lead: 2024 BSG Guidelines for the management of IBD in adults

Guideline Development Group Lead: 2024 BSG Guidelines for the management of IBD in adults


Expressions of interest for position of Guideline Development Group Lead

2024 British Society of Gastroenterology Guidelines for the management of inflammatory bowel disease in adults

Following publication of the British Society of Gastroenterology (BSG) guidelines for the management of inflammatory bowel disease in adults in December 2019, the IBD Section Committee is planning the next iteration of the IBD guidelines with a view to publication in 2024.

At this time the Chair and Secretary of the IBD Section Committee wish to seek expressions of interest from any interested member of the BSG who would like to be considered for the position of Guideline Development Group (GDG) lead. This individual is anticipated to act as senior author (or first author) for the 2024 guideline.

Various models to deliver the IBD guideline could be utilised. It is encouraged that a trainee should be appointed competitively either by the successful applicant or through the BSG to work with the GDG lead to deliver this document. The trainee could be appointed as a fellow with a view to undertaking a PhD or MD, for example in evidence synthesis and quality improvement. In this eventuality, the GDG lead would be expected to seek funds or have access to a funded position to appoint a fellow. An alternative model would be for the GDG lead to act as lead author for the guideline alongside a senior mentor identified by the GDG lead or through competitive appointment by the BSG. The GDG lead will be expected to submit a conflict of interest (CoI) declaration to the BSG Clinical Standards and Services Committee and depending on CoI the BSG may need to appoint an independent Chair of the GDG to oversee potential conflicts. Following the appointment, the GDG lead will see expressions of interest and competitively appoint a wider guideline group. Further details of the guideline development process are provided below:

Guideline objectives:

1. To provide high-quality disease management guidance for IBD clinicians.
2. To ensure treatment decisions are based on the best available evidence and consensus expert opinion in order to promote best practice.
3. Where appropriate the guidelines will refer to relevant NICE guidance, and other aspects of IBD management within the NHS.
4. To ensure the guidelines are patient-centred.


Professionals involved in IBD care (doctors, specialist nurses, and other allied professional groups treating and supporting IBD patients). Patient centred and patient accessible but written for a clinical audience.

Guideline development group:

Interested members of British Society of Gastroenterology IBD Section. GDG likely to form Autumn 2021. Additional representatives from non-adult gastroenterologist professional groups:
• IBD Specialist nurses/RCN: Adult and paediatric IBD nurse specialists
• BSPGHAN: Paediatric gastroenterologist(s)
• ACPGBI: Colorectal surgeon(s)
• Crohn’s & Colitis UK: Patient(s) representation
• BSGAR: Radiologist(s)
• PCSG/RCGP: General Practitioner(s)
• BDA: Dietitian(s)

Anticipated methodology:

• GRADE methodology compliant
• NICE compliant
• Regular reporting of expressions of interest
• Systematic review of literature will be undertaken to identify appropriate evidence to underpin guideline development
• The GDG will confirm that the recommendations cover all relevant clinical questions for each section of the guidelines
• Draft recommendations will be reviewed by Crohn’s Colitis UK and other Stakeholders named above.
• Recommendations GRADEd where appropriate
• Three rounds minimum of eDelphi. Consensus defined as ≥80% agreement.
• PPI involvement throughout. Consider repeat of research prioritisation exercise with Crohn’s & Colitis UK undertaken during 2019 guideline development